Trametinib
- PDF / 169,827 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 85 Downloads / 129 Views
1 S
Multiple toxicities: 11 case reports. In a retrospective study conducted between 2016 and 2018, 11 patients (6 males and 5 females) aged 7.3–25.9 years were described, who developed skin toxicity, intracranial haemorrhage, intratumoral petechial haemorrhage or retinal pigment epithelial detachment during off label treatment with trametinib for pediatric low-grade gliomas [pLGGs; not all outcomes stated]. All the patients with recurrent or progressive pLGGs were enrolled in the study and started receiving off label treatment with trametinib 0.025 mg/kg daily [route not stated]. All the patients were previously treated with unspecified treatments. A female patient discontinued trametinib 1 week after initiation due to intracranial haemorrhage. With intensive rehabilitation, she regained some degree of functional strength. Remaining 10 patients developed skin toxicity (unspecified). Of whom, 2 male patients developed significant intracranial haemorrhage and intratumoral petechial haemorrhage 16.4 months and 22.0 months of trametinib initiation, respectively. The man with intracranial haemorrhage also had an atraumatic and acute neurological worsening with alteration of mental status and suffered from short-term memory loss, swallow and speech dysfunction, which did not significantly recovered despite intensive rehabilitation. Of the 10 patients, a female patient developed retinal pigment epithelial detachment requiring treatment interruption and dose reduction, which resolved symptoms after stopping treatment for 4 weeks. The trametinib was restarted at 75% dosing with no relapse of retinal pigment epithelial detachment. Manoharan N, et al. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. Journal of Neuro-Oncology 149: 253-262, No. 2, Sep 2020. Available 803519293 from: URL: http://doi.org/10.1007/s11060-020-03592-8
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
